Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Uprosertib in Recurrent/Persistent Cervical Cancer
NCT01958112Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Oct 2013
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of uprosertib in Cervical Cancer (CC), sponsored by Dana-Farber Cancer Institute. Started Oct 2013; status: terminated.
02
Drugs
uprosertib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT01958112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01958112.